Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$44.03 USD
-0.16 (-0.36%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $44.02 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
RYTM 44.03 -0.16(-0.36%)
Will RYTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
Other News for RYTM
Rhythm Pharmaceuticals Q2 2024 Earnings Preview
Stifel Nicolaus Reaffirms Their Buy Rating on Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Announces European Commission Expands ?IMCIVREE? (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
Rhythm Pharmaceuticals announces expansion of IMCIVREE marketing authorization
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity